MUTANTE INTERLEUKIN-2-POLYPEPTIDE

European patent · EP3489255 · In force

Register entry

Publication number
EP3489255
Application number
EP18191941
Kind
European patent with effect for Switzerland and Liechtenstein
Status
In force
Specification
Granted
Filed
Feb 7, 2012
Published
May 29, 2019
Granted
Jun 16, 2021
Protection ends at the latest
Feb 6, 2032
Next annual fee due
Feb 28, 2027
IPC classes
A61P 35/00 (2006.01)
A61P 37/04 (2006.01)
C07K 14/55 (2006.01)
A61K 38/20 (2006.01)
A61K 47/68 (2017.01)
Priority
EP 11153964 10.02.2011
EP 11164237 29.04.2011
Filing language
English
Source
Swissreg

History

What the Federal Institute of Intellectual Property published about this title, newest first.

  1. Mar 1, 2026

    Change

    Published in Swissreg on 01.03.2026

  2. Mar 1, 2025

    Change

    Published in Swissreg on 01.03.2025

  3. Mar 1, 2024

    Change

    Published in Swissreg on 01.03.2024

  4. Mar 6, 2023

    Change

    Published in Swissreg on 06.03.2023

  5. Apr 27, 2022

    Change

    Published in Swissreg on 27.04.2022

  6. Jun 16, 2021

    Granted

    Published in Swissreg on 16.06.2021

Parties

Holder

Roche Glycart AG

Wagistrasse 10, 8952 Schlieren

Inventor

FREIMOSER-GRUNDSCHOBER, Anne

8050 Zuerich

HOFER, Thomas U.

8052 Zuerich

HOSSE, Ralf

6330 Cham

NICOLINI, Valeria G.

8703 Erlenbach/ZH

HERTER, Sylvia

8105 Regensdorf

KLEIN, Christian

8906 Bonstetten

BRUENKER, Peter

8335 Hittnau

MOESSNER, Ekkehard

8280 Kreuzlingen

UMANA, Pablo

8832 Wollerau

AST, Oliver

8303 Bassersdorf

The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.